Cardiology

Vigilance and Vital Signs: Monitoring Your Recovery

At a Glance

After coronary thrombosis and a heart attack, follow-up lipid testing, medication reviews, and an echocardiogram when needed help track recovery. Call 911 for new chest pain, severe breathing trouble, fainting, major bleeding, or symptoms of stent thrombosis.

Leaving the hospital is a major milestone, but it shifts the responsibility of monitoring from a medical team to you. The weeks and months following a heart attack are a period of high alert where your body is healing and adapting to new medications. Understanding what to watch for—and knowing when a symptom is a minor side effect versus a life-threatening emergency—is the core of your long-term safety plan.

The Follow-Up Roadmap

Your recovery is tracked through a series of “checkpoints” designed to catch issues before they become emergencies.

Lipid Panels: You should have your follow-up blood test roughly 4 to 12 weeks after discharge or a medication change to check lipids ^[1]. This ensures your LDL-C (bad cholesterol) is dropping toward the target. If it isn’t, your doctor may add a second medication ^[2]^[3]. (Note: Tests for kidney function or potassium may be scheduled much earlier if you start certain blood pressure drugs.)
Heart Function (LVEF): If your heart attack weakened your heart’s pumping strength—measured as Left Ventricular Ejection Fraction (LVEF)—you will likely need a repeat echocardiogram 6 to 12 weeks after the event ^[4]. This “convalescent” measurement is more accurate than the one taken during the heart attack because it shows how much the muscle has actually recovered ^[5]^[6].
Medication Review: Early follow-up appointments are critical for “medication reconciliation”—checking that you are taking the right doses and not experiencing side effects that make you want to stop the drugs ^[7]^[8].

Red Flags: When to Call 911

Some symptoms after a heart attack require immediate emergency intervention. Do not drive yourself to the hospital; call emergency services if you experience:

Recurrent Chest Pain: Any pressure, tightness, or squeezing in the chest, even if it feels “milder” than your first heart attack ^[9]^[10].
Signs of Heart Failure: Sudden breathlessness at rest, an inability to lie flat without struggling to breathe, fainting, sustained palpitations, or rapidly worsening swelling with weight gain.
Signs of Stent Thrombosis: This is a rare but dangerous event where a clot forms suddenly inside your new stent ^[11]. It often feels exactly like a new heart attack and can include sudden shortness of breath, heavy sweating, fainting, or extreme weakness ^[10]^[12].
Major Bleeding: Because you are likely on Dual Antiplatelet Therapy (DAPT), your blood is less prone to clotting, which increases bleeding risks ^[13]. Seek emergency care for:
- Vomiting blood (may look like coffee grounds).
- Blood in your stool (bright red) or black, tarry stools.
- A sudden, severe “thunderclap” headache, confusion, or a heavy fall (signs of bleeding in the brain) ^[14]^[15].

Managing Bleeding on DAPT

It is very common to notice “nuisance” bleeding while taking aspirin and a second antiplatelet medicine. You do not usually need to stop your medication for these, but you should mention them to your doctor:

Minor Bleeding: Easy bruising, small nosebleeds that stop with pressure, or gums bleeding during brushing are expected ^[16]^[17].
Moderate Bleeding: If you have a nosebleed that won’t stop after 10-15 minutes or blood in your urine, call your cardiologist’s office immediately ^[18]^[19]. They may temporarily adjust your dose, but you must never stop these medications on your own, as the risk of a clot forming in your stent is highest in the first few months ^[20]^[21]. (Never delay emergency care for severe bleeding while trying to follow this rule.)

The Role of Ejection Fraction (LVEF)

Your LVEF is one of the most important numbers for your long-term outlook.

Recovery: Many patients see their LVEF improve as “stunned” heart muscle wakes up following a stent procedure ^[5].
Persistent Low EF: If your LVEF remains at or below 35% after a waiting period of optimal medical therapy (typically at least 40 days to 3 months depending on the specifics of your care), your doctor may evaluate your symptoms and rhythm history to discuss more advanced protections, such as an Implantable Cardioverter Defibrillator (ICD), to protect against dangerous heart rhythms ^[4]^[6].

Monitoring these numbers and symptoms isn’t just about looking for problems—it’s about confirming that your heart is actively healing ^[22].

Common questions in this guide

When should I have follow-up tests after coronary thrombosis?

A lipid panel is generally checked about 4 to 12 weeks after discharge or a medication change. If your heart’s pumping strength was reduced, a repeat echocardiogram is often done 6 to 12 weeks after the event. Kidney function or potassium may need to be checked sooner with certain blood pressure medicines.

What symptoms mean I should call 911 after a heart attack?

Call 911 for new or recurrent chest pressure, tightness, or squeezing, especially with sweating or weakness. Severe shortness of breath, trouble breathing when lying flat, fainting, sustained palpitations, or rapidly worsening swelling and weight gain also require emergency care. Do not drive yourself to the hospital.

What does a low LVEF mean after coronary thrombosis?

LVEF measures how well the heart’s main pumping chamber pushes out blood. It may improve as temporarily stunned heart muscle recovers. If it remains at or below 35% after a period of optimal medical therapy, your doctor may discuss an implantable cardioverter-defibrillator based on your symptoms and heart-rhythm history.

Should I stop aspirin or my other antiplatelet medicine if I bruise?

Easy bruising, small nosebleeds that stop with pressure, and bleeding gums can occur with dual antiplatelet therapy. Do not stop these medicines on your own because stopping them can increase the risk of a clot in a coronary stent, particularly during the first few months. Tell your cardiologist about ongoing or concerning bleeding.

Which types of bleeding are an emergency while taking antiplatelet medicines?

Seek emergency care for vomiting blood, bright-red blood in the stool, black tarry stools, or a sudden severe headache with confusion or after a heavy fall. A nosebleed that does not stop after 10 to 15 minutes or blood in the urine should prompt an immediate call to your cardiologist’s office. Do not delay emergency care for severe bleeding.

Curated prompts to bring to your next appointment.

1.What was my ejection fraction (LVEF) at discharge, and when is my follow-up echocardiogram scheduled to reassess it?
2.Are my current LDL cholesterol levels meeting the target, or do we need to adjust my statin or add another medication?
3.Based on my bleeding and clotting risk scores, how long must I stay on both of my antiplatelet medications?
4.If I notice minor bruising or a small nosebleed, should I call your office or just monitor it at home?
5.At what point would my heart function be considered stable enough to move from 'close monitoring' to 'long-term maintenance'?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

A follow-up lipid panel is generally checked 4 to 12 weeks after discharge or a medication change, while kidney or potassium tests may be needed sooner with some medicines.
If the heart’s pumping strength was weakened, a repeat echocardiogram 6 to 12 weeks after the event helps reassess LVEF after recovery begins.
Call 911 for recurrent chest pressure, severe breathlessness, fainting, sustained palpitations, rapidly worsening swelling, or major bleeding.
Minor bruising, small nosebleeds, and bleeding gums can occur with dual antiplatelet therapy, but antiplatelet medicines should never be stopped without cardiologist guidance.
A persistent LVEF of 35% or less after optimal medical therapy may prompt discussion of an implantable cardioverter-defibrillator based on symptoms and heart-rhythm history.

References (22)

1
Singapore expert consensus on optimising lipid-lowering strategies in acute coronary syndrome: A modified Delphi study.
Tan RS, Yap J, Yeo C, et al.
Annals of the Academy of Medicine, Singapore 2026; (55(6)):318-331 doi:10.47102/annals-acadmedsg.2025459.
PMID: 42249756
2
PENELOPE 1-year follow-up: legacy effect of a short protocol-led LDL-C-lowering strategy in patients after myocardial infarction.
van der Brug S, van Trier T, Omar Khader A, et al.
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2025; (33(4)):120-129 doi:10.1007/s12471-025-01939-2.
PMID: 39994164
3
Dyslipidemia Treatment in Patients with Acute Coronary Syndrome: Is It Time to Move to Combination Therapy?
Brie DM, Mornoș C, Adam O, et al.
Journal of clinical medicine 2025; (14(18)) doi:10.3390/jcm14186445.
PMID: 41010649
4
Does stress echocardiography add incremental value to baseline ejection fraction for the early identification of candidates for implantable defibrillators?
Muhrbeck J, Gunyeli E, Andersson E, et al.
Open heart 2019; (6(2)):e001053 doi:10.1136/openhrt-2019-001053.
PMID: 31363415
5
Evaluation of changes in perfusion defect and left ventricular systolic function using Tc-99m Tetrofosmin single photon emission computed tomography over 3 month period in patients of Acute Myocardial Infarction undergoing primary angioplasty.
Kumar AA, Kumar PG, Swami A, Dinker Y
Nuclear medicine review. Central & Eastern Europe 2018; (21(1)):1-7 doi:10.5603/NMR.a2018.0001.
PMID: 29319132
6
ST-elevation myocardial infarction with reduced left ventricular ejection fraction: Insights into persisting left ventricular dysfunction. A pPCI-registry analysis.
Stolfo D, Cinquetti M, Merlo M, et al.
International journal of cardiology 2016; (215()):340-5.
PMID: 27128558
7
Telemedicine Improves the Short-Term Medical Care of Acute ST-Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention.
Kamel H, Hafez MS, Bastawy I
Frontiers in cardiovascular medicine 2021; (8()):693731 doi:10.3389/fcvm.2021.693731.
PMID: 34322529
8
Evidence-Based Clinical Decision Support to Improve Care for Patients Hospitalized With Acute Myocardial Infarction.
Fry C, Engel J, Granger B, et al.
Computers, informatics, nursing : CIN 2023; (41(5)):323-329 doi:10.1097/CIN.0000000000000959.
PMID: 35942719
9
Incidence and prognosis of stent thrombosis following percutaneous coronary intervention in Middle Eastern patients: The First Jordanian Percutaneous Coronary Intervention Registry (JoPCR1).
Saleh A, Hammoudeh A, Tabbalat R, et al.
Annals of Saudi medicine 2016; (36(1)):17-22 doi:10.5144/0256-4947.2016.17.
PMID: 26922683
10
Stent thrombosis: an updated clinical overview from epidemiology to classification and management.
Granata LG, Marchetta M, Alagna G, et al.
Heart (British Cardiac Society) 2026; doi:10.1136/heartjnl-2026-327899.
PMID: 42103453
11
Peculiarities of in-Stent Thrombosis and Restenosis in Coronary Arteries Post-COVID-19: A Systematic Review of Clinical Cases and Case Series.
Pivina L, Batenova G, Omarov N, et al.
Open access emergency medicine : OAEM 2025; (17()):15-30 doi:10.2147/OAEM.S470523.
PMID: 39872756
12
A nightmare of clopidogrel resistance in a resource-limited setting: case report of subacute stent thrombosis.
Pallangyo P, Bhalia SV, Komba M, et al.
The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 2023; (75(1)):85 doi:10.1186/s43044-023-00408-8.
PMID: 37823944
13
Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease.
Lettino M, Leonardi S, De Maria E, Halvorsen S
European journal of preventive cardiology 2017; (24(3_suppl)):61-70 doi:10.1177/2047487317707854.
PMID: 28618904
14
Resumption of Antiplatelet Therapy after Major Bleeding.
Geisler T, Poli S, Huber K, et al.
Thrombosis and haemostasis 2023; (123(2)):135-149 doi:10.1055/s-0042-1750419.
PMID: 35785817
15
Intracranial Hemorrhage During Dual Antiplatelet Therapy: JACC Review Topic of the Week.
Ha ACT, Bhatt DL, Rutka JT, et al.
Journal of the American College of Cardiology 2021; (78(13)):1372-1384 doi:10.1016/j.jacc.2021.07.048.
PMID: 34556323
16
1-Month Versus 12-Month Dual Antiplatelet Therapy for Patients with Chronic Total Occlusion After Successful Percutaneous Coronary Intervention.
Zhao S, Zhu B, Chen Y, et al.
Drugs & aging 2025; (42(10)):975-985 doi:10.1007/s40266-025-01235-z.
PMID: 40751899
17
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.
Valgimigli M, Frigoli E, Heg D, et al.
The New England journal of medicine 2021; (385(18)):1643-1655 doi:10.1056/NEJMoa2108749.
PMID: 34449185
18
Hematuria Management in Patients on Antiplatelet Medications After Acute Coronary Syndrome: A Review of the Current Evidence and Recommendations.
Loufopoulos I, Kapriniotis K, Fyntanidou B, et al.
Reviews in cardiovascular medicine 2026; (27(3)):46334 doi:10.31083/RCM46334.
PMID: 41923731
19
[Severe bleeding with antiplatelet therapy: What to do?]
Cayla G, Cornillet L, Ledermann B, et al.
Presse medicale (Paris, France : 1983) 2019; (48(12)):1416-1421 doi:10.1016/j.lpm.2019.08.017.
PMID: 31679898
20
Prasugrel or ticagrelor monotherapy vs dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndromes: a landmark analysis from the NEOMINDSET trial.
Tavares CAM, Guimarães PO, Franken M, et al.
European heart journal 2025; doi:10.1093/eurheartj/ehaf1050.
PMID: 41412791
21
P2Y12 inhibitor monotherapy after abbreviated dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis.
Spagnolo M, Imbesi A, Bordonaro CA, et al.
European heart journal 2026; doi:10.1093/eurheartj/ehag381.
PMID: 42247196
22
Left Ventricular Ejection Fraction Trajectory and Long-Term Outcomes Following Percutaneous Coronary Intervention for Myocardial Infarction.
Sampath-Kumar R, von Koch S, Mohammad MA, et al.
JACC. Advances 2026; (5(7)):102881 doi:10.1016/j.jacadv.2026.102881.
PMID: 42314580

This page explains follow-up monitoring after coronary thrombosis for informational purposes only and does not replace medical advice. Contact your cardiology team or emergency services for symptoms or bleeding concerns.

Get notified when new evidence is published on coronary thrombosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents